Standard BioTools Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $20.1M | $21.1M | — | — | — | $19.6M | — |
| Cost of Revenue | — | $9.6M | $9.8M | — | — | — | $10.1M | — |
| Gross Profit | — | $10.5M | $11.3M | — | — | — | $9.5M | — |
| Gross Margin | — | 52.4% | 53.5% | — | — | — | 48.5% | — |
| Operating Expenses | ||||||||
| Research & Development | — | $2.0M | $2.1M | — | — | — | $6.4M | — |
| SG&A Expense | — | $16.4M | $18.6M | — | — | — | $26.6M | — |
| Operating Income | — | $-25.4M | $-12.5M | — | — | — | $-32.9M | — |
| Operating Margin | — | -126.3% | -59.1% | — | — | — | -168.5% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-21.4M | $-14.6M | — | — | — | $-32.9M | — |
| Income Tax Expense | — | $90.0K | $11.0K | — | — | — | $-1.2M | — |
| Net Income | — | $-26.8M | $127.1M | — | — | — | $-34.7M | — |
| Net Margin | — | -133.1% | 600.9% | — | — | — | -177.4% | — |
| EPS (Basic) | — | $-0.07 | $0.33 | — | — | — | $-0.09 | — |
| EPS (Diluted) | — | $-0.07 | $0.33 | — | — | — | $-0.09 | — |
| Shares Outstanding (Basic) | 392.6M | 390.9M | 388.2M | 390.1M | 386.4M | 384.6M | 382.6M | 382.0M |
| Shares Outstanding (Diluted) | 392.6M | 390.9M | 388.2M | 390.1M | 386.4M | 384.6M | 382.6M | 382.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |